

AUTHOR INDEX FOR VOLUME 27

A

- Adams, Adrienne, Jarrott, Bevyn, Elmes, Bryan C., Denny, William A., and Wakelin, Laurence P. G.** Interaction of DNA-Intercalating Antitumor Agents with Adrenoceptors, 480
- Akamatsu, Nobu**, See *Shima, Hirai, and Kouyama*, 218
- Alberts, Alfred W.**, See *Chao, Pickett, Yamin, Guo, and Kroon*, 394
- Albuquerque, Edson X.**
See *Sherby, Eldefrawi, and Eldefrawi*, 343
See *Spivak*, 246
- Alexander, R. Wayne**, See *Colucci, Brock, and Gimbrone*, 517
- Allan, Paula W.**, See *Bennett, Brockman, Rose, Shaddix, Shealy, and Clayton*, 666
- Allen, D. T.**, See *Marks, Johnston, Sutherland, Nakatsu, and Whitney*, 459
- Allen, Matthew, and Tu, Anthony T.** The Effect of Tryptophan Modification on the Structure and Function of a Sea Snake Neurotoxin, 79
- Alm, Gunnar**, See *Dencker, Hassoun, and d'Argy*, 133
- Anderson, Leojean**, See *Schellenberg, Cragoe, and Swanson*, 537
- Appelman, Evan H.**, See *Li, Purdy, Klicka, and Li*, 559
- Avbelj, F., and Hadži, D.** Potential Energy Functions and the Role of the Conformational Entropy of Clonidine-like Imidazolidines in Determining Their Affinity for α -Adrenergic Receptors, 466
- Axworthy, Donald B.**, See *Hoffmann, Streeter, and Baillie*, 566
- Azari, J.**, See *Heasley and Brunton*, 60

B

- Bahouth, Suleiman W., Lazaro, Deana M., Brundish, Derek E., and Musacchio, José M.** Specific Binding of [3 H-Tyr 4]Physalamin to Rat Submaxillary Gland Substance P Receptor, 38
- Baillie, Thomas A.**, See *Hoffmann, Streeter, and Axworthy*, 566
- Bales, John R.**, See *Nicholson, Timbrell, and Sadler*, 634
- Balzarini, Jan, De Clercq, Erik, Herdewijn, Piet, and Robins, Morris J.** Role of Thymidine Kinase and Thymidylate Synthetase in the Cytostatic, Antimetabolic, and Antitumor Effects of the Carbocyclic Analogue of 5-Nitro-2'-deoxyuridine, a Comparison with 5-Nitro-2'-deoxyuridine, 578
- Batra, Janendra K., Jurd, Leonard, and Hamel, Ernest.** Structure-Function Studies with Derivatives of 6-Benzyl-1,3-benzodioxole, a New Class of Synthetic Compounds Which Inhibit Tubulin Polymerization and Mitosis, 94
- Battistoni, Claudio**, See *Cellai, Cerrini, Segre, Cossu, Mattogno, Brufani, and Marchi*, 103
- Bennett, L. Lee, Jr., Brockman, R. Wallace, Rose, Lucy M., Allan, Paula W., Shaddix, Sue C., Shealy, Y. Fulmer, and Clayton, Joe D.** Inhibition of Utilization of Hypoxanthine and Guanine in Cells Treated with the Carbocyclic Analog of Adenosine: Phosphates of Carbocyclic Nucleoside Analogs as Inhibitors of Hypoxanthine (Guanine) Phosphoribosyltransferase, 666
- Bergman, Åke**, See *Lund, Brandt, Poellinger, Klasson-Wehler, and Gustafsson*, 314
- Billings, Ruth E.**, See *Dankovic, Seifert, and Stillwell*, 287
- Bock, Karl Walter**, See *Lilienblum and Bock-Hennig*, 451
- Bockaert, Joël**, See *Weiss, Sebben, and Garcia-Sainz*, 595
- Bock-Hennig, Barbara S.**, See *Lilienblum and Bock*, 451
- Boothman, David A., Briggie, Thomas V., and Greer, Sheldon.** Metabolic Channeling of 5-Fluoro-2'-deoxycytidine Utilizing Inhibitors of Its Deamination in Cell Culture, 584
- Bowen, Wayne D.**, See *Rothman, Herkenham, Jacobson, Rice, and Pert*, 399
- Bradford, Peter G., and Rubin, Ronald P.** Characterization of Formylmethionyl-Leucyl-Phenylalanine Stimulation of Inositol Trisphosphate Accumulation in Rabbit Neutrophils, 74
- Brandt, Ingvar**, See *Lund, Poellinger, Bergman, Klasson-Wehler, and Gustafsson*, 314
- Braun, Deborah**, See *Lazo, Hait, Kennedy, and Meandžija*, 387
- Briggie, Thomas V.**, See *Boothman and Greer*, 584
- Brock, Tommy A.**, See *Colucci, Gimbrone, and Alexander*, 517
- Brockman, R. Wallace**, See *Bennett, Rose, Allan, Shaddix, Shealy, and Clayton*, 666
- Brodersen, Rolf**, See *Larsen, Larsen, and Jakobsen*, 263
- Brown, Joan Heller**
Goldstein, David, and Masters, Susan Brown. The Putative M $_1$ Muscarinic Receptor Does Not Regulate Phosphoinositide Hydrolysis: Studies with Pirenzepine and McN-A343 in Chick Heart and Astrocytoma Cells, 525
See *Masters and Quinn*, 325
- Brufani, Giulia**, See *Cellai, Cerrini, Segre, Battistoni, Cossu, Mattogno, and Marchi*, 103
- Brundish, Derek E.**, See *Bahouth, Lazaro, and Musacchio*, 38
- Brunton, L. L.**, See *Heasley and Azari*, 60
- Bulger, William H., Feil, Vernon J., and Kupfer, David.** Role of Hepatic Monooxygenases in Generating Estrogenic Metabolites from Methoxychlor and from Its Identified Contaminants, 115

C

- Caron, Marc G.**, See *Dickinson, Heald, Jeffs, and Leftkowitz*, 499
- Carter, Edward A.**, See *Schwarz, Lanier, Homcy, and Graham*, 200
- Cass, Carol E., Gati, Wendy P., Odegard, R., and Paterson, A. R. P.** The Effect of pH on Interaction of Nitrobenzylthioinosine and Hydroxynitrobenzylthioinosine with the Nucleoside Transporter of Human Erythrocyte Membranes, 662
- Catterall, William A.**, See *Willow and Gonoj*, 549
- Cellai, Luciano, Cerrini, Silvio, Segre, Annalaura, Battistoni, Claudio, Cossu, Gianni, Mattogno, Giulia, Brufani, Mario, and Marchi, Egidio.** A Study of Structure-Activity Relationships in 4-Deoxyprido[1',2'-1,2]imidazo[5,4-c]rifamycin SV Derivatives by Electron Spectroscopy for Chemical Analysis and 1 H NMR, 103
- Cerrini, Silvio**, See *Cellai, Segre, Battistoni, Cossu, Mattogno, Brufani, and Marchi*, 103
- Chan, Kenneth K.**, See *Moran, Colman, Rosowsky, and Forsch*, 156
- Chao, Yu-Sheng, Pickett, Cecil B., Yamin, Ting-Ting, Guo, Luke S. S., Alberts, Alfred W., and Kroon, Paulus A.** Phenobarbital Induces Rat Liver Apolipoprotein A-I mRNA, 394
- Clayton, Joe D.**, See *Bennett, Brockman, Rose, Allan, Shaddix, and Shealy*, 666
- Cohen, Marvin B.**
and Glazer, Robert I. Cytotoxicity and the Inhibition of Ribosomal RNA Processing in Human Colon Carcinoma Cells, 308
Comparison of the Cellular and RNA-Dependent Effects of Sangivamycin and Toyocamycin in Human Colon Carcinoma Cells, 349
- Colman, Paul D.**, See *Moran, Rosowsky, Forsch, and Chan*, 156
- Colucci, Wilson S., Brock, Tommy A., Gimbrone, Michael A., Jr., and Alexander, R. Wayne.** Nonlinear Relationship between α_1 -Adrenergic Receptor Occupancy and Norepinephrine-Stimulated Calcium Flux in Cultured Vascular Smooth Muscle Cells, 517
- Conn, P. Michael**, See *Harris and Staley*, 532
- Contreras, Renato**, See *Klopman*, 86

- Cossu, Gianni, See Cellai, Cerrini, Segre, Battistoni, Mattogno, Brufani, and Marchi, 103
 Cragoe, Edward J., Jr., See Schellenberg, Anderson, and Swanson, 537
 Creese, Ian
 See Leff, 184
 See Leff and Hamblin, 171
 Crespi, Charles L., See Friedman, Robinson, Song, Park, Marletta, and Gelboin, 652
 Crooke, Stanley T., See Hogaboom, Mong, and Stadel, 236

D

- Danenberg, Peter V., See Spears, Shani, Shahinian, Wolf, and Heidelberg, 302
 Dankovic, David, Billings, Ruth E., Seifert, William, and Stillwell, Wanda G. Bromobenzene Metabolism in Isolated Rat Hepatocytes: $^{18}\text{O}_2$ Incorporation Studies, 287
 Dannan, Ghazi A., See Steward, Guzelian, and Guengerich, 125
 d'Argy, Roland, See Dencker, Hassoun, and Alm, 133
 De Clercq, Erik, See Balzarini, Herdewijn, and Robins, 578
 Dencker, Lennart, Hassoun, Ezdihar, d'Argy, Roland, and Alm, Gunnar. Fetal Thymus Organ Culture as in *Vitro* Model for the Toxicity of 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin and Its Congeners, 133
 Denny, William A., See Adams, Jarrott, Elmes, and Wakelin, 480
 Denomme, M. A., Homonoko, K., Fujita, T., Sawyer, T., and Safe, S. Effects of Substituents on the Cytosolic Receptor-Binding Avidities and Aryl Hydrocarbon Hydroxylase Induction Potencies of 7-Substituted 2,3-Dichlorodibenzo-*p*-dioxins: A Quantitative Structure-Activity Relationship Analysis, 656
 Dickinson, Kenneth E. J., Heald, Sarah L., Jeffs, Peter W., Lefkowitz, Robert J., and Caron, Marc G. Covalent Labeling of the β -Adrenergic Ligand-Binding Site with *para*-(Bromoacetamidyl)benzylcarazolol: A Highly Potent β -Adrenergic Affinity Label, 499
 Doss, Robert C., Kramarcy, Neal R., Harden, T. Kendall, and Perkins, John P. Effects of Tunicamycin on the Expression of β -Adrenergic Receptors in Human Astrocytoma Cells during Growth and Recovery from Agonist-Induced Down-regulation, 507

E

- Ehrlich, Yigal H., See Lenox, Ellis, and Van Riper, 1
 Eldefrawi, Amira T., See Sherby, Albuquerque, and Eldefrawi, 343
 Eldefrawi, Mohyee E., See Sherby, Eldefrawi, and Albuquerque, 343
 Eling, Thomas E., See Reed and Griffin, 109
 Ellis, John, See Lenox, Van Riper, and Ehrlich, 1
 Elmes, Bryan C., See Adams, Jarrott, Denny, and Wakelin, 480
 Enna, S. J., See Karbon, 53
 Epand, R. M., Stafford, A. R., Tyers, M., and Nieboer, E. Mechanism of Action of Diabetogenic Zinc-Chelating Agents: Model System Studies, 366
 Evans, F. E., See Hinson, Freeman, Potter, and Mitchum, 574
 Evans, Tony, Martin, Michael W., Hughes, Arlene R., and Harden, T. Kendall. Guanine Nucleotide-Sensitive, High Affinity Binding of Carbachol to Muscarinic Cholinergic Receptors of 1321N1 Astrocytoma Cells Is Insensitive to Pertussis Toxin, 32

F

- Feil, Vernon J., See Bulger and Kupfer, 115
 Fesik, Stephen W., and Makriyannis, Alexandros. Geometric Requirements for Membrane Perturbation and Anesthetic Activity: Conformational Analysis of Alphaxalone and Δ^6 -Alphaxalone and ^2H NMR Studies on Their Interactions with Model Membranes, 624
 Forsch, Ronald A.
 See Moran, Colman, Rosowsky, and Chan, 156
 See Rosowsky, Galivan, Susten, and Freisheim, 141

- Freeman, J. P., See Hinson, Potter, Mitchum, and Evans, 574
 Freisheim, James H., See Rosowsky, Forsch, Galivan, and Susten, 141
 Friedman, Fred K., Robinson, Richard C., Song, Byung-Joon, Park, Sang Shin, Crespi, Charles L., Marletta, Michael A., and Gelboin, Harry V. Monoclonal Antibody-Directed Determination of Cytochrome P-450 Types Expressed in a Human Lymphoblastoid Cell Line, 652
 Froede, H. C., and Wilson, I. B. The Slow Rate of Inhibition of Acetylcholinesterase by Fluoride, 630
 Fujita, T., See Denomme, Homonoko, Sawyer, and Safe, 656

G

- Galivan, John, See Rosowsky, Forsch, Susten, and Freisheim, 141
 Garcia-Sainz, J. Adolfo, See Weiss, Sebben, and Bockaert, 595
 Gati, Wendy P., See Cass, Odegard, and Paterson, 662
 Gelboin, Harry V., See Friedman, Robinson, Song, Park, Crespi, and Marletta, 652
 Gianni, Luca, See Muindi, Sinha, and Myers, 356
 Gimbrone, Michael A., Jr., See Colucci, Brock, and Alexander, 517
 Glazer, Robert I., See Cohen, 308, 349
 Goldblum, Amiram, See Loew, 375
 Goldstein, David, See Brown and Masters, 525
 Goldstein, J. A., See Hardwick and Linko, 676
 Gommeren, W., See Leysen, Van Gompel, Wynants, Janssen, and Laduron, 600
 Gonoi, Tohru, See Willow and Catterall, 549
 Graham, Robert M., See Schwarz, Lanier, Carter, and Homcy, 200
 Greer, Sheldon, See Boothman and Briggie, 584
 Griffin, Irene O., See Reed and Eling, 109
 Griffin, J., See Watanabe, Mitchell, Sariban, Sabbath, and Kufe, 683
 Guan, J. H., See Niznik, Neumeyer, and Seeman, 193
 Guengerich, F. Peter, See Steward, Dannan, and Guzelian, 125
 Gullberg, Donald, See Poellinger, 271
 Guo, Luke S. S., See Chao, Pickett, Yamin, Alberts, and Kroon, 394
 Gustafsson, Jan-Åke
 See Lund, Brandt, Poellinger, Bergman, and Klasson-Wehler, 314
 See Morgan and MacGeoch, 471
 Guzelian, Philip S., See Steward, Dannan, and Guengerich, 125

H

- Hadzi, D., See Aubelj, 466
 Hait, William N., See Lazo, Kennedy, Braun, and Meandžija, 387
 Hamblin, Mark W., See Leff and Creese, 171
 Hamel, Ernest, See Batra and Jurd, 94
 Hansch, Corwin, McClarin, Judith, Klein, Teri, and Langridge, Robert. A Quantitative Structure-Activity Relationship and Molecular Graphics Study of Carbonic Anhydrase Inhibitors, 493
 Harden, T. Kendall
 See Doss, Kramarcy, and Perkins, 507
 See Evans, Martin, and Hughes, 32
 Hardwick, J. P., Goldstein, J. A., and Linko, P. Dose Response for Induction of Two Cytochrome P-450 Isozymes and Their mRNAs by (*E*)-4,5,3',4',5'-Hexachlorobiphenyl Indicating Coordinate Regulation in Rat Liver, 676
 Harris, Cynthia E., Staley, Daphne, and Conn, P. Michael. Diacylglycerols and Protein Kinase C: Potential Amplifying Mechanism for Ca^{2+} -Mediated Gonadotropin-Releasing Hormone-Stimulated Luteinizing Hormone Release, 532
 Hassoun, Ezdihar, See Dencker, d'Argy, and Alm, 133
 Hauswirth, William W., See Singh, Ross, and Neims, 167
 Heald, Sarah L., See Dickinson, Jeffs, Lefkowitz, and Caron, 499
 Heasley, L. E., Azari, J., and Brunton, L. L. Export by Cyclic AMP from Avian Red Cells: Independence from Major Membrane Transporters and Specific Inhibition by Prostaglandin A_1 , 60
 Heidelberg, Charles, See Spears, Shani, Shahinian, Wolf, and Danenberg, 302

- Herbette, Leo G., See *Rhodes and Sariato*, 612
 Herdewijn, Piet, See *Balzarini, De Clercq, and Robins*, 578
 Herkenham, Miles, See *Rothman, Bowen, Jacobson, Rice and Pert*, 399
 Hiller, Jacob M., See *Itzhak and Simon*, 46
 Hinson, J. A., Freeman, J. P., Potter, D. W., Mitchum, R. K., and Evans, F. E. Mechanism of Microsomal Metabolism of Benzene to Phenol, 574
 Hirai, Masanao, See *Shima, Akamatsu, and Kouyama*, 218
 Hoffman, Brian B., See *Tsujimoto*, 210
 Hoffmann, Kurt-Jurgen, Streeter, Anthony J., Axworthy, Donald B., and Baillie, Thomas A. Identification of the Major Covalent Adduct Formed *in Vitro* and *in Vivo* between Acetaminophen and Mouse Liver Proteins, 566
 Hogaboom, G. Kurt, Mong, Seymour, Stadel, Jeffrey M., and Crooke, Stanley T. Characterization of Guinea Pig Myocardial Leukotriene C₄ Binding Sites: Regulation by Cations and Sulfhydryl-Directed Reagents, 236
 Homcy, Charles J., See *Schwarz, Lanier, Carter, and Graham*, 200
 Homonoko, K., See *Denomme, Fujita, Sawyer, and Safe*, 656
 Howlett, Allyn C. Cannabinoid Inhibition of Adenylate Cyclase: Biochemistry of the Response in Neuroblastoma Cell Membranes, 429
 Hughes, Arlene R., See *Evans, Martin, and Harden*, 32

I

- Insel, Paul A., See *Snavely and Ziegler*, 19
 Itzhak, Yossef, Hiller, Jacob M., and Simon, Eric J. Characterization of Specific Binding Sites for [³H](d)-N-Allylnormetazocine in Rat Brain Membranes, 46

J

- Jacobson, Arthur E., See *Rothman, Bowen, Herenham, Rice, and Pert*, 399
 Jakobsen, Preben, See *Larsen, Larsen, and Brodersen*, 263
 Janssen, P. F. M., See *Leysen, Gommeren, Van Gompel, Wynants, and Laduron*, 600
 Jarrott, Bevy, See *Adams, Elmes, Denny, and Wakelin*, 480
 Jeffs, Peter W., See *Dickinson, Heald, Lefkowitz, and Caron*, 499
 Johnson, Eric F., See *Raucy*, 296
 Johnson, Randolph M., and Lincoln, Thomas M., Effects of Nitroprusside, Glyceryl Trinitrate, and 8-Bromo Cyclic GMP on Phosphorylase α Formation and Myosin Light Chain Phosphorylation in Rat Aorta, 333
 Johnston, C. T., See *Marks, Allen, Sutherland, Nakatsu, and Whitney*, 459
 Jurd, Leonard, See *Batra and Hamel*, 94

K

- Karbon, E. W., and Enna, S. J. Characterization of the Relationship between γ -Aminobutyric Acid B Agonists and Transmitter-Coupled Cyclic Nucleotide-Generating Systems in Rat Brain, 53
 Kennedy, Katherine A., See *Lazo, Hait, Braun, and Meandzija*, 387
 Klasson-Wehler, Eva, See *Lund, Brandt, Poellinger, Bergman, and Gustafsson*, 314
 Klein, Teri, See *Hansch, McClarin, and Langridge*, 493
 Klicka, John K., See *Li, Purdy, Appelman, and Li*, 559
 Kloog, Yoel, and Sokolovsky, Mordechai. Bisquaternary Pyridinium Oximes as Allosteric Inhibitors of Rat Brain Muscarinic Receptors, 418
 Klopman, Gilles, and Contreras, Renato. Use of Artificial Intelligence in Structure-Activity Correlations of Anticonvulsant Drugs, 86
 Kouyama, Hiroshi, See *Shima, Akamatsu, and Hirai*, 218
 Kramarcy, Neal R., See *Doss, Harden, and Perkins*, 507
 Kroon, Paulus A., See *Chao, Pickett, Yamin, Guo, and Alberts*, 394

- Kufe, D., See *Watanabe, Mitchell, Sariban, Sabbath, and Griffin*, 683
 Kupfer, David, See *Bulger and Feil*, 115

L

- Laduron, P. M., See *Leysen, Gommeren, Van Gompel, Wynants, and Janssen*, 600
 Langridge, Robert, See *Hansch, McClarin, and Klein*, 493
 Langa, David A., and Triggle, David J. Conformational Features of Calcium Channel Agonist and Antagonist Analogs of Nifedipine, 544
 Lanier, Stephen M., See *Schwarz, Carter, Homcy, and Graham*, 200
 Larsen, Christian Grønhoj, See *Larsen, Jakobsen, and Brodersen*, 263
 Larsen, Frederik Grønhoj, Larsen, Christian Grønhoj, Jakobsen, Preben, and Brodersen, Rolf. Interaction of Warfarin with Human Serum Albumin: A Stoichiometric Description, 263
 Larsson, Roger, See *Ross, Norbeck, Ryhage, and Moldéus*, 277
 Laychock, Suzanne G., Phosphatidylethanolamine N-Methylation and Insulin Release in Isolated Pancreatic Islets of the Rat, 66
 Lazaro, Deana M., See *Bahouth, Brundish, and Musacchio*, 38
 Lazo, John S., Hait, William N., Kennedy, Katherine A., Braun, Deborah, and Meandzija, Borislav. Enhanced Bleomycin-Induced DNA Damage and Cytotoxicity with Calmodulin Antagonists, 387
 Leff, Stuart E. and Creese, Ian. Interactions of Dopaminergic Agonists and Antagonists with Dopaminergic D₂ Binding Sites in Rat Striatum: Evidence that [³H]Dopamine Can Label a High Affinity Agonist-Binding State of the D₁ Dopamine Receptor, 184
 Hamblin, Mark W., and Creese, Ian. Interactions of Dopamine Agonists with Brain D₁ Receptors Labeled by ³H-Antagonists: Evidence for the Presence of High and Low Affinity Agonist-Binding States, 171
 Lefkowitz, Robert J., See *Dickinson, Heald, Jeffs, and Caron*, 499
 Lenox, Robert H., Ellis, John, Van Riper, Dee, and Ehrlich, Yigal H. α_2 -Adrenergic Receptor-Mediated Regulation of Adenylate Cyclase in the Intact Human Platelet: Evidence for a Receptor Reserve, 1
 Leysen, J. E., Gommeren, W., Van Gompel, P., Wynants, J., Janssen, P. F. M., and Laduron, P. M. Receptor-Binding Properties *in Vitro* and *in Vivo* of Ritanerlin: A Very Potent and Long Acting Serotonin-S₂ Antagonist, 600
 Li, Jonathan J., Purdy, Robert H., Appelman, Evan H., Klicka, John K., and Li, Sara Antonia. Catechol Formation of Fluoro- and Bromo-Substituted Estradiols by Hamster Liver Microsomes, 559
 Li, Sara Antonia, See *Li, Purdy, Appelman, and Klicka*, 559
 Lilienblum, Werner, Bock-Hennig, Barbara S., and Bock, Karl Walter. Protection against Toxic Redox Cycles between Benzo[a]pyrene-3,6-quinone and Its Quinol by 3-Methylcholanthrene-Inducible Formation of the Quinol Mono- and Diglucuronide, 451
 Lincoln, Thomas M., See *Johnson*, 333
 Linko, P., See *Hardwick and Goldstein*, 676
 Loew, Gilda H., and Goldblum, Amiram. Metabolic Activation and Toxicity of Acetaminophen and Related Analogs: a Theoretical Study, 375
 Lund, Johan, Brandt, Ingvar, Poellinger, Lorenz, Bergman, Åke, Klasson-Wehler, Eva, and Gustafsson, Jan-Åke. Target Cells for the Polychlorinated Biphenyl Metabolite 4,4'-Bis(methylsulfonyl)-2,2',5,5'-tetrachlorobiphenyl: Characterization of High Affinity Binding in Rat and Mouse Lung Cytosol, 314

M

- MacGeoch, Catriona, See *Morgan, and Gustafsson*, 471
 Magruder, Janet D., Waid-Jones, Madeline, and Reitz, Ronald C. Ethanol-Induced Alterations in Rat Synaptosomal Plasma

- Membrane Phospholipids: Relationship to Changes in the Phospholipid Methyltransferases, 256
- Makriyannis, Alexandros**, See *Fesik*, 624
- Marchi, Egidio**, See *Cellai, Cerrini, Segre, Battistoni, Cossu, Mattogno, and Brufani*, 103
- Marks, Gerald S., Allen, D. T., Johnston, C. T., Sutherland, E. P., Nakatsu, K., and Whitney, R. A.** Suicidal Destruction of Cytochrome P-450 and Reduction of Ferrochelatase Activity by 3,5-Diethoxycarbonyl-1,4-dihydro-2,4,6-trimethylpyridine and Its Analogues in Chick Embryo Liver Cells, 459
- Marletta, Michael A.**, See *Friedman, Robinson, Song, Park, Crespi, and Gelboin*, 652
- Marsh, James D., and Smith, Thomas W.** Receptors for β -Adrenergic Agonists in Cultured Chick Ventricular Cells: Relationship between Agonist Binding and Physiologic Effect, 10
- Martin, Michael W.**, See *Evans, Hughes, and Harden*, 32
- Masters, Susan Brown, Quinn, Mark T., and Brown, Joan Heller.** Agonist-Induced Desensitization of Muscarinic Receptor-Mediated Calcium Efflux without Concomitant Desensitization of Phosphoinositide Hydrolysis, 325
See *Brown and Goldstein*, 525
- Mattogno, Giulia**, See *Cellai, Cerrini, Segre, Battistoni, Cossu, Brufani, and Marchi*, 103
- McClarín, Judith**, See *Hansch, Klein, and Langridge*, 493
- McGee, Richard, Jr.**, See *Robinson*, 409
- McKinney, M., Stenstrom, S., and Richelson, E.** Muscarinic Responses and Binding in a Murine Neuroblastoma Clone (N1E-115): Mediation of Separate Responses by High Affinity and Low Affinity Agonist-Receptor Conformations, 223
- Meandžija, Borislav**, See *Lazo, Hait, Kennedy, and Braun*, 387
- Mitchell, T.**, See *Watanabe, Sariban, Sabbath, Griffin, and Kufe*, 683
- Mitchum, R. K.**, See *Hinson, Freeman, Potter, and Evans*, 574
- Mohammed, S. Noor**, A Quantum Mechanical Approach to the Theory of Cancer from Polymorphonuclear Compounds: Metabolic Activation and Carcinogenicity of Extended Anilines and Aminoazo Compounds, 148
- Moldéus, Peter**, See *Ross, Larsson, Norbeck, and Ryhage*, 277
- Mong, Seymour**, See *Hogaboom, Stadel, and Croke*, 236
- Moran, Richard G., Colman, Paul D., Rosowsky, Andre, Forsch, Ronald A., and Chan, Kenneth K.** Structural Features of 4-Amino Antifolates Required for Substrate Activity with Mammalian Polypolyglutamate Synthetase, 156
- Morgan, Edward T., MacGeoch, Catriona, and Gustafsson, Jan-Åke** Sexual Differentiation of Cytochrome P-450 in Rat Liver: Evidence for a Constitutive Isozyme as the Male-Specific 16 α -Hydroxylase, 471
- Muindi, Josephia, Sinha, Birandra K., Gianni, Luca, and Myers, Charles.** Thiol-Dependent DNA Damage Produced by Anthracycline-Iron Complexes: the Structure-Activity Relationships and Molecular Mechanisms, 356
- Musacchio, José M.**, See *Bahouth, Lazaro, and Brundish*, 38
- Myers, Charles**, See *Muindi, Sinha, and Gianni*, 356
- N**
- Nakatsu, K.**, See *Marks, Allen, Johnston, Sutherland, and Whitney*, 459
- Neims, Allen H.**, See *Singh, Hauswirth, and Ross*, 167
- Neumeyer, J. L.**, See *Niznik, Guan, and Seeman*, 193
- Nicholson, Jeremy K.**
Timbrell, John A., Bales, John R., and Sadler, Peter J. A. High Resolution Proton Nuclear Magnetic Resonance Approach to the Study of Hepatocyte and Drug Metabolism: Application to Acetaminophen, 634
Timbrell, John A., and Sadler, Peter J. Proton NMR Spectra of Urine as Indicators of Renal Damage: Mercury-Induced Nephrotoxicity in Rats, 644
- Nieboer, E.**, See *Epand, Stafford, and Tyers*, 366
- Niznik, H. B., Guan, J. H., Neumeyer, J. L., and Seeman, P. A.** Photoaffinity Ligand for Dopamine D₂ Receptors: Azidocleopride, 193
- Norbeck, Kajsa**, See *Ross, Larsson, Ryhage, and Moldéus*, 277
- O**
- Odegard, R.**, See *Cass, Gati, and Paterson*, 662
- P**
- Page, Jimmy D., Wilson, I. B., and Silman, Israel.** Butyrylcholinesterase: Inhibition by Arsenite, Fluoride, and Other Ligands, Cooperativity in Binding, 437
- Park, Sang Shin**, See *Friedman, Robinson, Song, Crespi, Marletta, and Gelboin*, 652
- Paterson, A. R. P.**, See *Cass, Gati, and Odegard*, 662
- Perkins, John P.**, See *Doss, Kramarcy, and Harden*, 507
- Pert, Candace B.**, See *Rothman, Bowen, Herkenham, Jacobson, and Rice*, 399
- Pickett, Cecil B.**, See *Chao, Yamin, Guo, Alberts, and Kroon*, 394
- Poellinger, Lorenz, and Gullberg, Donald.** Characterization of the Hydrophobic Properties of the Receptor for 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin, 271
See *Lund, Brandt, Bergman, Klasson-Wehler, and Gustafsson*, 314
- Potter, D. W.**, See *Hinson, Freeman, Mitchum, and Evans*, 574
- Purdy, Robert H.**, See *Li, Appelman, Klicka, and Li*, 559
- Q**
- Quinn, Mark T.** See *Masters and Brown*, 325
- R**
- Raess, Beat U., Record, Donna M., and Tunnicliff, Godfrey.** Interaction of Phenylglyoxal with the Human Erythrocyte [Ca²⁺+Mg²⁺]-ATPase: Evidence for the Presence of an Essential Arginyl Residue, 444
- Raucy, Judy L., and Johnson, Eric F.** Variations among Untreated Rabbits in Benzo(a)pyrene Metabolism and Its Modulation by 7,8-Benzoflavone, 296
- Record, Donna M.**, See *Raess and Tunnicliff*, 444
- Reed, Gregory A., Griffin, Irene O., and Eling, Thomas E.** Activation of Prostaglandin H Synthase and Prostacyclin Synthase by Phenylbutazone: Requirement for Peroxidative Metabolism, 109
- Reitz, Ronald C.**, See *Magruder and Waid-Jones*, 256
- Rhodes, David G., Sarmiento, J. George, and Herbette, Leo G.** Kinetics of Binding of Membrane-Active Drugs to Receptor Sites: Diffusion-Limited Rates for a Membrane Bilayer Approach of 1,4-Dihydropyridine Calcium Channel Antagonists to Their Active Site, 612
- Rice, Kenner C.**, See *Rothman, Bowen, Herkenham, Jacobson, and Pert*, 399
- Richelson, E.**, See *McKinney and Stenstrom*, 223
- Robins, Morris J.**, See *Balzarini, De Clercq, and Herdewijn*, 578
- Robinson, Denise, and McGee, Richard, Jr.** Agonist-Induced Regulation of the Neuronal Nicotinic Acetylcholine Receptor of PC12 Cells, 409
- Robinson, Richard C.**, See *Friedman, Song, Park, Crespi, Marletta, and Gelboin*, 652
- Rose, Lucy M.**, See *Bennett, Brockman, Allan, Shaddix, Shealy, and Clayton*, 666
- Rosowsky, Andre, Forsch, Ronald A., Galivan, John, Susten, Sandra S., and Freisheim, James H.** Regiospecific γ -Conjugation of Methotrexate to Poly(L-lysine): Chemical and Biological Studies, 141
See *Moran, Rosowsky, Forsch, and Chan*, 156
- Ross, David, Larsson, Roger, Norbeck, Kajsa, Ryhage, Ragnar, and Moldéus, Peter.** Characterization and Mechanism of Formation of Reactive Products Formed during Peroxidase-Catalyzed Oxidation of *p*-Phenetidine: Trapping of Reactive Species by Reduced Glutathione and Butylated Hydroxyanisole, 277

- Ross, Warren E., See *Singh, Hauswirth, and Neims*, 167
 Rothman, Richard B., Bown, Wayne D., Herkenham, Miles, Jacobson, Arthur E., Rice, Kenner C., and Pert, Candace B. A Quantitative Study of ^3H -Ala 1 -;D-Leu 6 -Enkephalin Binding to Rat Brain Membranes: Evidence That Oxymorphone Is a Non-competitive Inhibitor of the Lower Affinity δ -Binding Site, 399
 Rubin, Ronald P., See *Bradford*, 74
 Ryhage, Ragnar, See *Ross, Larsson, Norbeck, and Moldéus*, 277

S

- Sabbath, K., See *Watanabe, Mitchell, Sariban, Griffin, and Kufe*, 683
 Sadler, Peter J.
 See *Nicholson, Timbrell, and Bales*, 634
 See *Nicholson and Timbrell*, 644
 Safe, S., See *Denomme, Homonoko, Fujita, and Sawyer*, 656
 Sariban, E., See *Watanabe, Mitchell, Sabbath, Griffin, and Kufe*, 683
 Sarmiento, J. George, See *Rhodes and Herbette*, 612
 Sawyer, T., See *Denomme, Homonoko, Fujita, and Safe*, 656
 Schellenberg, Gerard D., Anderson, Leojean, Cragoe, Edward J., Jr., and Swanson, Phillip D. Inhibition of Synaptosomal Membrane Na^+ - Ca^{2+} Exchange Transport by Amiloride and Amiloride Analogues, 537
 Schreiber, Gabriel, and Sokolovsky, Mordechai. Muscarinic Receptor Heterogeneity Revealed by Interaction with Bretylium Tosylate: Different Ligand-Receptor Conformations versus Different Receptor Subclasses, 27
 Schwarz, Kurt R., Lanier, Stephen M., Carter, Edward A., Homcy, Charles J., and Graham, Robert M. Rapid Reciprocal Changes in Adrenergic Receptors in Intact Isolated Hepatocytes during Primary Cell Culture, 200
 Sebben, Michèle, See *Weiss, Garcia-Sainz, and Bockaert*, 595
 Seeman, P., See *Niznik, Guan, and Neumeyer*, 193
 Segre, Annalaura, See *Cellai, Cerrini, Battistoni, Cossu, Mattogno, Brufani, and Marchi*, 103
 Seifert, William, See *Dankovic, Billings, and Stillwell*, 287
 Shaddix, Sue C., See *Bennett, Brockman, Rose, Allan, Shealy, and Clayton*, 666
 Shahinian, Antranik H., See *Spears, Shani, Wolf, Heidelberger, and Danenberg*, 302
 Shani, Jashovam, See *Spears, Shahinian, Wolf, Heidelberger, and Danenberg*, 302
 Shealy, Y. Fulmer, See *Bennett, Brockman, Rose, Allan, Shaddix, and Clayton*, 666
 Sherby, Shebl M., Eldedfrawi, Amira T., Albuquerque, Edson X., and Eldefrawi, Mohyee E. Comparison of the Actions of Carbamate Anticholinesterases on the Nicotinic Acetylcholine Receptor, 343
 Shima, Sumio, Akamatsu, Nobu, Hirai, Masanao, and Kouyama, Hiroshi. Age-Related Alterations in the Catecholamine-Sensitive Adenylate Cyclase System of the Prostate, 218
 Silman, Israel, See *Page and Wilson*, 437
 Simon, Eric J., See *Itzhak and Hiller*, 46
 Singh, Gurmit, Hauswirth, William W., Ross, Warren E., and Neims, Allen H. A Method for Assessing Damage to Mitochondrial DNA Caused by Radiation and Epichlorohydrin, 167
 Sinha, Birandra K., See *Muindi, Gianni, and Myers*, 356
 Smith, Thomas W., See *Marsh*, 10
 Snavely, Marshall D., Ziegler, Michael G., and Insel, Paul A. A New Approach to Determine Rates of Receptor Appearance and Disappearance *in Vivo*: Application to Agonist-Mediated Down-regulation of Rat Renal Cortical β_1 - and β_2 -Adrenergic Receptors, 19
 Sokolovsky, Mordechai
 See *Kloog*, 418
 See *Schreiber*, 27
 Song, Byung-Joon, See *Friedman, Robinson, Park, Crespi, Marletta, and Gelboin*, 652
 Spears, C. Paul, Shani, Jashovam, Shahinian, Antranik H., Wolf, Walter, Heidelberger, Charles, and Danenberg, Peter

- V. Assay and Time Course of 5-Fluorouracil Incorporation into RNA of L1210/0 Ascites Cells *in Vivo*, 302
 Spivak, C. E., and Albuquerque, E. X. Triphenylmethylphosphonium Blocks the Nicotinic Acetylcholine Receptor Noncompetitively, 246
 Stadel, Jeffrey M., See *Hogaboom, Mong, and Crooke*, 236
 Stafford, A. R., See *Epan, Tyers, and Nieboer*, 366
 Staley, Daphne, See *Harris and Conn*, 532
 Stenstrom, S., See *McKinney and Richelson*, 223
 Steward, A. Ruth, Dannan, Ghazi A., Guzelian, Philip S., and Guengerich, F. Peter. Changes in the Concentration of Seven Forms of Cytochrome P-450 in Primary Cultures of Adult Rat Hepatocytes, 125
 Stillwell, Wanda G., See *Dankovic, Billings, and Seifert*, 287
 Streeter, Anthony, See *Hoffmann, Axworthy, and Baillie*, 566
 Susten, Sandra S., See *Rosowsky, Forsch, Galivan, and Freisheim*, 141
 Sutherland, E. P., See *Marks, Allen, Johnston, Nakatsu, and Whitney*, 459
 Swanson, Phillip D., See *Schellenberg, Anderson, and Cragoe*, 537

T

- Timbrell, John A.
 See *Nicholson, Bales, and Sadler*, 634
 See *Nicholson and Sadler*, 644
 Triggie, David J., See *Langs*, 544
 Tsujimoto, Gozoh, and Hoffman, Brian B. Desensitization of β -Adrenergic Receptor-Mediated Vascular Smooth Muscle Relaxation, 210
 Tu, Anthony T., See *Allen*, 79
 Tunnicliff, Godfrey, See *Raess and Record*, 444
 Tyers, M., See *Epan, Stafford, and Nieboer*, 366

V

- Van Gompel, P., See *Leysen, Gommeren, Wynants, Janssen, and Laduron*, 600
 Van Riper, Dee, See *Lenox, Ellis, and Ehrlich*, 1

W

- Waid-Jones, Madeline, See *Magruder and Reitz*, 256
 Wakelin, Laurence P. G., See *Adams, Jarrott, Elmes, and Denny*, 480
 Watanabe, T., Mitchell, T., Sariban, E., Sabbath, K., Griffin, J., and Kufe, D. Effects of 1- β -D-Arabinofuranosylcytosine and Phorbol Ester on Differentiation of Human K562 Erythroleukemia Cells, 683
 Weiss, Samuel, Sebben, Michèle, Garcia-Sainz, J. Adolfo, and Bockaert, Joël. D $_2$ -Dopamine Receptor-Mediated Inhibition of Cyclic AMP Formation in Striatal Neurons in Primary Culture, 595
 Whitney, R. A., See *Marks, Allen, Johnston, Sutherland, and Nakatsu*, 459
 Willow, Max, Gono, Tohru, and Catterall, William A. Voltage Clamp Analysis of the Inhibitory Actions of Diphenylhydantoin and Carbamazepine on Voltage-Sensitive Sodium Channels in Neuroblastoma Cells, 549
 Wilson, I. B.
 See *Froede*, 630
 See *Page and Silman*, 437
 Wolf, Walter, See *Spears, Shani, Shahinian, Heidelberger, and Danenberg*, 302
 Wynants, J., See *Leysen, Gommeren, Van Gompel, Janssen, and Laduron*, 600

Y

- Yamin, Ting-Ting, See *Chao, Pickett, Guo, Alberts, and Kroon*, 394

Z

- Ziegler, Michael G., See *Snavely and Insel*, 19

INSTRUCTIONS TO AUTHORS

Molecular Pharmacology will publish the results of investigations that contribute significant new information on drug action or selective toxicity at the molecular level. The term "drug" is defined broadly to include chemicals that selectively modify biological function.

Suitable papers are those that describe applications of the methods of biochemistry, biophysics, genetics, and molecular biology to problems in pharmacology or toxicology. Also suitable are reports of fundamental investigations which, although not concerned directly with drugs, nevertheless provide an immediate basis for further study of the molecular mechanism of drug action. Observations of phenomena that shed no light upon underlying molecular interactions are not appropriate for publication. Comparative studies, such as those involving drug-receptor or drug-enzyme interactions that already have been well characterized in other types of cells or tissues, also are inappropriate for publication unless they contribute significant new insight into mechanisms.

Specific areas of interest include: stereochemical, electronic, and other parameters of drug architecture; conformational analysis of receptors and their function; drug-enzyme and other interactions between drugs and macromolecules; drug effects upon gene replication and transcription and on protein synthesis; mechanism of action of antibiotics and other growth-inhibitory drugs; induction by drugs of changes in macromolecular structure or allosteric transitions; drug-induced alterations in metabolic pathways; effects of hormones and other drugs on cellular regulatory mechanisms; chemical mutagenesis, carcinogenesis, and teratogenesis; pharmacogenetics, idiosyncrasies, and drug allergies; selective toxicity in a single organism or in different species; drug actions on properties and functions of membranes; mechanisms of drug metabolism; distribution and transport of drug molecules between biological compartments.

Page charges. Authors will be billed at the rate of \$30.00 per page after the paper has been published. It is expected that the page charge will be paid if funds are available for that purpose from the author's institution or from the sponsor of this research. Payment of the charge is not a condition for publication. In case of personal financial hardship, page charges will be waived. Neither the editors nor the reviewers will have knowledge as to who has paid the charge, and this payment always will be considered entirely voluntary.

Submission of manuscript. Manuscripts are published in English only and should be sent to **Dr. Joel Hardman, Editor, *Molecular Pharmacology*, Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, U. S. A.**

The expenses associated with the review of manuscripts submitted to *Molecular Pharmacology* and other ASPET-sponsored journals that are devoted to publishing original research articles have escalated dramatically in recent years because of ever-increasing costs of postage, supplies, and other office expenses, and the growing number of manuscripts submitted for publication. Thus, it has become necessary for ASPET to follow the example of several other scientific societies which have instituted uniform manuscript handling fees. *Therefore, all manuscripts must be accompanied either by a check for \$30 (in U. S. funds drawn on a U. S. bank payable to ASPET) or by a validated purchase order from the authors' institution.* The review process for submitted manuscripts will be delayed until the manuscript handling fee or purchase order is received in the Editor's office. If submission of the manuscript handling fee entails a personal financial hardship to the author(s), the fee will be waived. In that event, the author(s) should submit a request for waiver of the fee when the manuscript is submitted.

Manuscripts should be typewritten double-spaced with ample margins on one side of the paper, 8½ × 11 inches (ca. 215 × 280 mm). Submit four complete copies of the manuscript and four copies of each figure, plus one original drawing or photograph of each figure. Each half-tone figure requires four original drawings or photographs. All pages should be numbered consecutively beginning with the title page. Limit your reference listings to the minimal number required to document the manuscript adequately. In most instances 30 references or fewer should suffice.

Under usual circumstances reviewers will be instructed to return only their comments to the editorial office and to destroy manuscripts after a final decision on their acceptability has been made.

Original drawings and single copies of manuscripts not accepted for publication will be returned to the authors upon request.

It is understood that the manuscripts and the results they contain will not have been published previously and are not being submitted elsewhere. Manuscripts are accepted for review with the understanding that all persons listed as authors have given their approval for the submission of the paper; further, that any person cited as a source of personal communications has approved such citation. Written authorization may be required at the Editor's discretion. Articles and any other material published in *Molecular Pharmacology* represent the opinions of the author(s) and should not be construed to reflect the opinions of the Editor(s) and the Publisher. If and when a manuscript is published, it will become the sole property of the Journal.

Authors submitting a manuscript do so on the understanding that if it is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the Society for Pharmacology and Experimental Therapeutics. No reasonable request by the author for permission to reproduce any of his or her contributions to the journal will be refused.

Organization and style of manuscripts. The policy of the Journal is to allow authors maximum freedom in organizing and presenting their material, and in expressing their ideas, provided only that clarity and conciseness are achieved. For most manuscripts, the most suitable format is: (1) Summary, (2) Introduction, (3) Materials and Methods, (4) Results, and (5) Discussion.

Certain conventions must be observed. Chemical and mathematical formulas and abbreviations should follow the *Instructions to Authors of the Journal of Biological Chemistry* (Vol. 260, pp. 1-11, January 10, 1985). Drugs must be referred to by their generic or chemical names throughout the text, but may be identified by trade name in parentheses or a footnote. The systematic name and number given by the Commission on Enzymes of the International Union of Biochemistry should be included for each enzyme of importance in a paper, at the point in the Summary or Introduction where the enzyme is first mentioned. The use of abbreviations should be minimized and abbreviations avoided in the Summary. All essential abbreviations should be defined in a single footnote when first introduced. Abbreviations of journal names should conform to the style of *Biological Abstracts*. References to papers that

have been accepted for publication, but have not appeared, should be cited like other references with the abbreviated name of the journal followed by the words "in press." Copies of such papers should be sent whenever the findings described in them have a direct bearing on the paper being submitted for publication. "Personal Communications" and "Unpublished Observations" should be cited in footnotes to the text and should not be included in the reference list.

A manuscript should include the following, in the order listed: (1) Title. Numbered footnotes to the title should be avoided; acknowledgment of financial support should be given in an unnumbered footnote to the title. (2) Names of authors, their laboratory and institution. (3) A running title, not exceeding 60 characters and spaces. (4) Summary. (5) Text. Footnotes should be referred to by superscript numbers and references by numbers in parentheses. (6) References, numbered according to order of citation in the text, including title and complete pagination. Examples: 1. Goren, J. H., L. G. Baue, and W. Vale. Forces and structural limitations of binding of thyrotropin-releasing receptor: the pyroglutamic acid moiety. *Mol. Pharmacol.* 13:606-614 (1977). 2. Chernow, B., and J. T. O'Brian. Overview of catecholamines in selected endocrine systems, in *Norepinephrine* (M. G. Ziegler and C. R. Lake, eds.). Williams and Wilkins, Baltimore, 439-449 (1984). 3. Snedecor, G. W., and W. G. Cochran. *Statistical Methods*. Iowa State University Press, Ames (1967). (7) Footnotes, numbered according to order of appearance in the text. (8) Tables. (9) Figures. (10) Legends to figures. (11) Name and address of person to receive galley proof.

Tables. These should be numbered with arabic numerals and designed to fit the single-column width of the full-page width. Every table should have an explanatory title and sufficient experimental detail in a paragraph following the title to be intelligible without references to the text (unless the procedure is given in the Methods section, or under another table or figure). Footnotes to tables should

appear beneath the tables themselves and should be designated by lower-case italic superscript letters, *a*, *b*, *c*, etc.

Figures. These should be numbered with arabic numerals. Each of the four manuscript copies should contain all of the figures. Only the original set need be of quality suitable for reproduction except in the case of half-tones, which require four sets of photographs or original drawings. These should be unmounted glossy photographs (or original India-ink drawings). Usually figures will be reduced to one column width (85 mm) and all numbers *after* such reduction should be at least 1.5 mm high. The figures must be ready, in all respects, for direct reproduction: no lettering or other art work will be done by the publisher. If symbols are not explained on the face of the figure, only standard characters, of which the printer has type, may be used (×, ○, ●, □, ■, △, ▲, ⊙). The back of each photograph should bear its number, and the legend TOP at the appropriate edge. The list of legends for the figures should give captions and sufficient experimental detail, as required for tables.

Page proof. Authors will be billed for substantial changes in page proof. The Editors are very much interested in having accepted contributions appear in the earliest possible issue of the Journal, and therefore request that galley proof be returned within 24 hours after its receipt. In exceptional cases, a "Note added in proof" may be attached and will be published if the Editor approves.

Reprints and page charges. An order form for reprints as well as information on the estimation of page charges will be mailed with galley proof. Please direct questions on reprints, page charges, or other business matters to Kay Croker, Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, Md. 20814. Telephone (301)530-7060.